Alarif L, Castro O, Ofosu M, Dunston G, Scott R B
Clin Immunol Immunopathol. 1986 Feb;38(2):178-83. doi: 10.1016/0090-1229(86)90136-4.
HLA-A, -B, -C, and DR antigens were determined in 33 patients with sickle cell disease (SCD), who had received red blood cell (RBC) transfusions. Twenty-one patients formed red cell alloantibodies after transfusions (responders) while 12 multitransfused SCD patients did not form any RBC antibodies (non-responders). We found that 67% of the SCD responder participants had HLA-B35 versus 25% of the non-responders (chi 2 = 5.3079, P = 0.0212). The frequency of B35 in non-responder SCD patients was similar to that of a normal healthy Black population consisting of 139 individuals. Calculation of the relative risk showed that sickle cell patients with B35 are six times more likely to form RBC alloantibodies after transfusion than those lacking that HLA antigen. We found no significant increase or association between any HLA-DR antigens and sickle cell disease.
对33例接受过红细胞（RBC）输血的镰状细胞病（SCD）患者进行了HLA - A、 - B、 - C和DR抗原检测。21例患者在输血后形成了红细胞同种抗体（反应者），而12例多次输血的SCD患者未形成任何RBC抗体（无反应者）。我们发现，67%的SCD反应者参与者有HLA - B35，而无反应者为25%（卡方 = 5.3079，P = 0.0212）。无反应的SCD患者中B35的频率与由139名个体组成的正常健康黑人人群相似。相对风险计算表明，携带B35的镰状细胞患者输血后形成RBC同种抗体的可能性是缺乏该HLA抗原患者的6倍。我们未发现任何HLA - DR抗原与镰状细胞病之间有显著增加或关联。
